370 related articles for article (PubMed ID: 33916057)
1. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
Reddig A; Voss L; Guttek K; Roggenbuck D; Feist E; Reinhold D
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916057
[TBL] [Abstract][Full Text] [Related]
2. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
5. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
Alten R; Mischkewitz M; Stefanski AL; Dörner T
Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
[TBL] [Abstract][Full Text] [Related]
6. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
[No Abstract] [Full Text] [Related]
8. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Mitchell TS; Moots RJ; Wright HL
Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
[TBL] [Abstract][Full Text] [Related]
11. Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes.
Yao N; Tretter T; Kvacskay P; Merkt W; Blank N; Lorenz HM; Tykocinski LO
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680530
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
Adam S; Simon N; Steffen U; Andes FT; Scholtysek C; Müller DIH; Weidner D; Andreev D; Kleyer A; Culemann S; Hahn M; Schett G; Krönke G; Frey S; Hueber AJ
Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051226
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.
Harrington R; Harkins P; Conway R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892827
[TBL] [Abstract][Full Text] [Related]
14. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Solipuram V; Mohan A; Patel R; Ni R
Auto Immun Highlights; 2021 Apr; 12(1):8. PubMed ID: 33910632
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis.
Chandrashekara S
Expert Opin Drug Metab Toxicol; 2024 Jun; ():. PubMed ID: 38916236
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
Drugs Context; 2019; 8():212595. PubMed ID: 31692920
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
18. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
Moura RA; Fonseca JE
Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
Deprez V; Le Monnier L; Sobhy-Danial JM; Grados F; Henry-Desailly I; Salomon-Goëb S; Rabin T; Ristic S; Fumery M; Fardellone P; Goëb V
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081099
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
Meudec L; Richebé P; Pascaud J; Mariette X; Nocturne G
Rheumatology (Oxford); 2023 Aug; 62(8):2855-2863. PubMed ID: 36583542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
